ARTICLE | Company News
Draxis receives Canadian approval
June 25, 2001 7:00 AM UTC
Draxis Health (DRAX; TSE:DAX) received Canadian marketing approval for its Levulan 20 percent aminolevulinic acid (ALA) oral photosensitizer combined with light therapy to treat actinic keratoses -- p...